Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02) is a phase 2, randomised interventional study registered as NCT06681038 by Institut Cancerologie de l'Ouest, with a registry enrolment figure of 114 participants, started 2025-02 and due to reach its primary completion in 2029-08. Interventions recorded: Standard Medical Therapy; PIPAC. Conditions listed: Peritoneal Metastases from Colorectal Cancer. Primary outcome: Progression free survival (PFS) between the two groups. Colorectal eligibility wording from the registry: "* Histopathologically confirmed colonic adenocarcinoma with synchronous or metachronous peritoneal metastasis (PM);". Sites: France. No results are recorded here; the registry entry is the source.